Ontario Capital Growth Corporation gains $19m as Affinium Pharmaceuticals is acquired by Swiss biopharmaceutical Debiopharm International.
Affinium Pharmaceuticals, a US-based biotechnology company backed by the Ontario Capital Growth Corporation, has been acquired by Debiopharm International, a Switzerland-based biopharmaceutical company.
The Ontario Capital Growth Corporation received $19m from the acquisition, more than three times its initial investment in the company when it took part in Affinium’s $15m series B round in August 2011 with Canada-based Genesys Capital Management, UK-based SV Life Science Advisors and US-based Forward Ventures Partners.
The Ontario Capital Growth Corporation is an agency of…
